1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Yuyu Pharma, Inc.

Yuyu Pharma, Inc.

000220.KS
Yuyu Pharma, Inc.KR flagKorea Exchange
3,800.00
KRW
-5.00
- -
59.84BMarket Cap
Yuyu Pharma, Inc.
000220.KS
(Korea Exchange)

Recent

price

3,800.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4,959.32
6,418.88
6,263.55
5,880.53
6,279
7,023.46
6,001.7
5,618.93
6,603.83
7,274.37
7,903.93
7,247.01
8,767.51
7,394.63
7,939.65
8,500.74
8,657.32
Revenue per Share
106.5
208.16
301
178
-746.43
-25.45
493.5
406
319.5
378
103.39
-138.72
-378
-387
520
492
546.04
Basic EPS, GAAP
516.83
674.4
553.61
-203.82
72.52
-1,399.71
628.78
-285.95
-314.68
356.11
-1,366.05
-140.5
-744.72
-252.51
1,052.27
447.92
261.51
Free Cash Flow per Basic Share
46.72
65.55
72.55
90.39
107.02
121.06
106.83
113.9
109.99
115.58
122.4
116
128.39
107.88
- -
116.4
- -
Dividend per Share
4,276
4,521.04
4,381.35
4,223.08
3,545.7
3,429.85
3,218.91
3,711.11
3,478.03
3,733.81
4,053.98
3,393.03
3,093.67
2,036.08
2,587.89
3,023.37
3,101.63
Book Value per Share
6,524.16
6,930.65
6,674.53
6,523.24
6,802.66
7,070.44
6,288.73
7,121.84
6,665.46
6,985.72
9,014.18
7,641.72
7,390.22
6,116.61
7,712.64
8,152.74
8,278.49
Tangible Book Value per Share
10
9
10
11
10
10
12
11
13
12
12
16
16
19
17
17
17
Basic Weighted Avg Shares
52,027
58,799
61,985
61,994
62,816
69,743
71,579
62,852
83,096
90,878
98,120
115,655
138,881
137,210
133,147
140,885
143,520
Sales/Revenue/Turnover
2.49
3.57
6
2.83
2.18
2.31
5.22
5.68
6.41
8.89
6.39
1.04
-0.43
0.27
9.45
7.82
7.95
Operating Margin (%)
2,246
1,695
1,549
1,633
1,510
1,542
1,601
1,461
2,127
3,121
3,899
4,503
5,027
5,607
5,666
5,608
5,622
Depreciation Expense
1,117
1,907
2,979
1,877
-7,467
-253
5,886
4,541
4,020
4,722
1,284
-2,214
-5,988
-7,181
8,720
8,154
9,052
Net Income, GAAP
- -
- -
16.74
26.53
- -
- -
5.99
10.9
7.23
15.71
34.99
- -
- -
- -
- -
3.86
5.35
Effective Tax Rate (%)
2.15
3.24
4.81
3.03
-11.89
-0.36
8.22
7.23
4.84
5.2
1.31
-1.91
-4.31
-5.23
6.55
5.79
6.31
Profit Margin (%)
17,660
16,822
20,201
28,344
22,673
19,809
25,453
27,987
41,082
22,558
46,068
68,873
32,042
51,621
37,468
37,967
38,291
Working Capital
- -
- -
200
3,956
- -
- -
- -
1,349
18,181
3,070
14,972
28,739
1,851
14,021
402
257
428
LT Debt
70,642
67,229
69,501
72,276
71,489
73,731
78,291
82,834
86,872
90,545
117,036
128,685
123,374
120,356
135,063
140,544
142,557
Total Equity
- -
- -
4.48
1.79
- -
- -
3.94
3.34
4.63
5.91
3.26
- -
- -
- -
- -
6.28
6.37
Return on Invested Capital (%)
- -
- -
6.72
4
- -
- -
10.82
8.5
6.7
7.02
1.72
- -
- -
- -
- -
10.58
11.77
Return on Capital (%)
2.51
4.42
7.03
4.27
-18.67
-0.73
16.25
11.37
9.43
10.45
2.65
-4.24
-11.61
-16.55
21.48
17.44
18.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
28,677
27,666
25,787
LT Borrowings
33
- -
- -
LT Finance Leases
244
257
428
Preferred Equity and Hybrid Capital
2,592
2,592
2,592
Shares Outstanding
16
16
16
Market Capitalization
72,664
76,297
68,715

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
96,665
96,914
94,788
Cash, Cash Equivalents & STI
28,669
32,705
29,887
Accounts Receivable, Net
20,826
18,553
20,060
Inventories
44,317
42,221
39,486
Total Current Liabilities
54,758
58,948
56,497
Payables & Accruals
- -
- -
- -
ST Debt
28,677
27,666
25,787
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7%
3.93%
4.06%
Free Cash Flow
-122.18%
-51.1%
-57.93%
Net Income, GAAP
-282.9%
-62%
-6.49%
Sales/Revenue/Turnover
7.96%
7.92%
5.81%
Total Cash Common Dividend
- -
- -
-3.63%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33,405
33,177
33,600
32,966
133,147
2025
32,907
35,846
37,792
34,339
140,885
2026
35,542
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
320
67
188
- -
520
2025
155
- -
233
- -
492
2026
217
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
116.4
2026
- -
- -
- -
- -
- -
Similar Companies
KYORIN Holdings, Inc. (4569.T)
Hester Biosciences Limited (HESTERBIO.NS)
Simply Better Brands Corp. (SBBC.V)
Nextage Therapeutics Ltd (NXTG.TA)
ECS Botanics Holdings Ltd (ECS.AX)
FSD Pharma Inc. (HUGE.CN)
Business
Yuyu Pharma, Inc. is a South Korean pharmaceutical company founded in 1941 and headquartered in Jecheon-si, South Korea. The company develops, manufactures, markets, and distributes a broad range of pharmaceutical products including prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, antidiabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, and topical corticosteroids. It also produces non-prescription drugs including vitamins and digestive agents, as well as healthcare supplements and quasi-drugs, targeting therapeutic areas including neurology, endocrinology, otolaryngology, osteoporosis, dementia, stroke, and chronic diseases. Yuyu Pharma operates primarily in South Korea and Southeast Asia. The company is recognized for its generic soft capsule Newmacor, an Omega-3-acid ethyl ester product for hypertriglyceridemia, which has been a leading product in its domestic market. Recently, Yuyu Pharma has established a strategic research partnership with UCLA University for multiple sclerosis treatment and is progressing in drug discovery programs addressing benign prostatic hyperplasia and dry eye syndrome. The company also focuses on developing species-specific animal therapeutics, including injectable monthly treatments for pets, and pursues collaborations with U.S. startups to advance diagnosis and treatment technologies for chronic animal diseases. Yuyu Pharma has invested in new and renewable energy facilities at its manufacturing site and continues to expand its pharmaceutical innovation and global reach while maintaining a public listing on the Korea Exchange since 1975. This profile reflects operations and developments as of late 2025.